联邦制药：受托人购入350万股奖励股份

Core Viewpoint - The company announced the purchase of 3.5 million shares at an average price of HKD 12.905 per share to fulfill its obligations under the share award plan for achieving 2024 performance targets [1] Group 1 - The trustee has acquired 3.5 million shares through market transactions [1] - The average purchase price per share was HKD 12.905 [1] - The shares will be held in trust until they vest to the relevant award recipients according to the terms of the share award plan [1] Group 2 - The trustee will continue to purchase additional shares depending on market conditions [1] - The shares are intended for individuals who have met the performance targets set for 2024 [1]